

Natpara® (parathyroid hormone) – Drug shortage

- The <u>drug shortage</u> of Takeda's <u>Natpara (parathyroid hormone)</u> injection is ongoing due to requirements related to complying with good manufacturing processes. Natpara has been unavailable for at least 90 days.
- In September 2019, Takeda announced a voluntary patient-level recall of all doses of Natpara due to a potential issue related to rubber particulates originating from the rubber septum of the Natpara cartridge. Takeda is working with the FDA to resolve this issue.
- Per Takeda, Natpara is only available through a <u>Special Use Program</u> that allocates Natpara to
 patients facing a life-threatening condition. The estimated availability of Natpara to the broader
 patient community is not known at this time.
- Natpara is a parathyroid hormone indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.

Product Description	Strength	NDC#
Natpara (parathyroid hormone) injection	25 mcg	68875-0202-01; 68875-0202-02
	50 mcg	68875-0203-01; 68875-0203-02
	75 mcg	68875-0204-01; 68875-0204-02
	100 mcg	68875-0205-01; 68875-0205-02



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.